Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 427 entries
Sorted by: Best Match Show Resources per page
Lead-210 in tobacco and cigarette smoke.

Public health reports (Washington, D.C. : 1896)

Ferri ES, Christiansen H.
PMID: 4963720
Public Health Rep. 1967 Sep;82(9):828-32.
Free PMC Article

No abstract available.

Cite
Ferri ES, Christiansen H. Lead-210 in tobacco and cigarette smoke. Public Health Rep. 1967;82(9):828-32
Ferri, E. S., & Christiansen, H. (1967). Lead-210 in tobacco and cigarette smoke. Public health reports (Washington, D.C. : 1896), 82(9), 828-32.
Ferri, E S, and Christiansen, H. "Lead-210 in tobacco and cigarette smoke." Public health reports (Washington, D.C. : 1896) vol. 82,9 (1967): 828-32.
Ferri ES, Christiansen H. Lead-210 in tobacco and cigarette smoke. Public Health Rep. 1967 Sep;82(9):828-32. PMID: 4963720; PMCID: PMC1920022.
Copy Download .nbib Format: NLM
Tumour karyotype may be important in the prognosis of human neuroblastoma.

Journal of cancer research and clinical oncology

Franke F, Rudolph B, Christiansen H, Harbott J, Lampert F.
PMID: 3733856
J Cancer Res Clin Oncol. 1986;111(3):266-72. doi: 10.1007/BF00389243.

When comparing clinical and tumour cytogenetic data on 14 neuroblastoma patients in different stages of disease we found a high incidence of 1p abnormalities (12/12), homogeneously staining regions/double minutes (9/12) and 2p abnormalities (4/12) in 12 unresectable and metastatic...

Cite
Franke F, Rudolph B, Christiansen H, et al. Tumour karyotype may be important in the prognosis of human neuroblastoma. J Cancer Res Clin Oncol. 1986;111(3):266-72doi: 10.1007/BF00389243.
Franke, F., Rudolph, B., Christiansen, H., Harbott, J., & Lampert, F. (1986). Tumour karyotype may be important in the prognosis of human neuroblastoma. Journal of cancer research and clinical oncology, 111(3), 266-72. https://doi.org/10.1007/BF00389243
Franke, F, et al. "Tumour karyotype may be important in the prognosis of human neuroblastoma." Journal of cancer research and clinical oncology vol. 111,3 (1986): 266-72. doi: https://doi.org/10.1007/BF00389243
Franke F, Rudolph B, Christiansen H, Harbott J, Lampert F. Tumour karyotype may be important in the prognosis of human neuroblastoma. J Cancer Res Clin Oncol. 1986;111(3):266-72. doi: 10.1007/BF00389243. PMID: 3733856.
Copy Download .nbib Format: NLM
[Tumor cytogenetics and prognosis in neuroblastoma].

Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde

Christiansen H, Lampert F.
PMID: 2586532
Monatsschr Kinderheilkd. 1989 Oct;137(10):666-71.

In 40 children with neuroblastoma of different clinical stages the tumorkaryotype was determined at onset (n = 30) or at relapse (n = 10) of disease after short-term culture of tumor tissues or bone marrow aspirates. None of the...

Cite
Christiansen H, Lampert F. Tumorcytogenetik und Prognose beim Neuroblastom. [Tumor cytogenetics and prognosis in neuroblastoma]. Monatsschr Kinderheilkd. 1989;137(10):666-71
Christiansen, H., & Lampert, F. (1989). Tumorcytogenetik und Prognose beim Neuroblastom. [Tumor cytogenetics and prognosis in neuroblastoma]. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 137(10), 666-71.
Christiansen, H, and Lampert, F. "Tumorcytogenetik und Prognose beim Neuroblastom." [Tumor cytogenetics and prognosis in neuroblastoma]. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde vol. 137,10 (1989): 666-71.
Christiansen H, Lampert F. Tumorcytogenetik und Prognose beim Neuroblastom. [Tumor cytogenetics and prognosis in neuroblastoma]. Monatsschr Kinderheilkd. 1989 Oct;137(10):666-71. German. PMID: 2586532.
Copy Download .nbib Format: NLM
[Laparoscopic sterilization with thermocoagulation].

Ugeskrift for laeger

Buchhave PK, Christiansen H, Sandholm LE.
PMID: 6210985
Ugeskr Laeger. 1982 Jan 18;144(3):147-9.

No abstract available.

Cite
Buchhave PK, Christiansen H, Sandholm LE. Laparoskopisk sterilisation med termokoagulation. [Laparoscopic sterilization with thermocoagulation]. Ugeskr Laeger. 1982;144(3):147-9
Buchhave, P. K., Christiansen, H., & Sandholm, L. E. (1982). Laparoskopisk sterilisation med termokoagulation. [Laparoscopic sterilization with thermocoagulation]. Ugeskrift for laeger, 144(3), 147-9.
Buchhave, P K, et al. "Laparoskopisk sterilisation med termokoagulation." [Laparoscopic sterilization with thermocoagulation]. Ugeskrift for laeger vol. 144,3 (1982): 147-9.
Buchhave PK, Christiansen H, Sandholm LE. Laparoskopisk sterilisation med termokoagulation. [Laparoscopic sterilization with thermocoagulation]. Ugeskr Laeger. 1982 Jan 18;144(3):147-9. Danish. PMID: 6210985.
Copy Download .nbib Format: NLM
Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas.

Medical and pediatric oncology

Poremba C, Hero B, Heine B, Scheel C, Schaefer KL, Christiansen H, Berthold F, Kneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B.
PMID: 11107139
Med Pediatr Oncol. 2000 Dec;35(6):651-5. doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i.

BACKGROUND: As traditional parameters do not ensure completely accurate prognostic grouping in neuroblastoma (NB), new molecular markers are needed for assessing the individual patient's prognosis more precisely.PROCEDURE, RESULTS, AND CONCLUSIONS: Based on 133 NB, we show that telomerase activity...

Cite
Poremba C, Hero B, Heine B, et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol. 2000;35(6):651-5doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i.
Poremba, C., Hero, B., Heine, B., Scheel, C., Schaefer, K. L., Christiansen, H., Berthold, F., Kneif, S., Stein, H., Juergens, H., Boecker, W., & Dockhorn-Dworniczak, B. (2000). Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Medical and pediatric oncology, 35(6), 651-5. https://doi.org/10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i
Poremba, C, et al. "Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas." Medical and pediatric oncology vol. 35,6 (2000): 651-5. doi: https://doi.org/10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i
Poremba C, Hero B, Heine B, Scheel C, Schaefer KL, Christiansen H, Berthold F, Kneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol. 2000 Dec;35(6):651-5. doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i. PMID: 11107139.
Copy Download .nbib Format: NLM
Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.

Medical and pediatric oncology

Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B.
PMID: 11464859
Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M.

PROCEDURE: To establish the significance of chromosome 17 aberrations in the biology of neuroblastomas, the fresh-frozen material of 53 primary neuroblastomas (average patient age: 20.8 months; stage 1 or 2: n = 10; stage 3: n = 10; stage...

Cite
Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001;36(1):11-3doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M.
Brinkschmidt, C., Christiansen, H., Terpe, H. J., Simon, R., Lampert, F., Boecker, W., & Dockhorn-Dworniczak, B. (2001). Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Medical and pediatric oncology, 36(1), 11-3. https://doi.org/10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M
Brinkschmidt, C, et al. "Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome." Medical and pediatric oncology vol. 36,1 (2001): 11-3. doi: https://doi.org/10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M. PMID: 11464859.
Copy Download .nbib Format: NLM
A prospective comparison of four antihypertensive agents in daily clinical practice.

Journal of clinical hypertension (Greenwich, Conn.)

Campo C, Segura J, Fernández ML, Guerrero L, Christiansen H, Ruilope LM.
PMID: 11430394
J Clin Hypertens (Greenwich). 2001 May-Jun;3(3):139-44. doi: 10.1111/j.1524-6175.2001.00448.x.

No abstract available.

Cite
Campo C, Segura J, Fernández ML, et al. A prospective comparison of four antihypertensive agents in daily clinical practice. J Clin Hypertens (Greenwich). 2001;3(3):139-44doi: 10.1111/j.1524-6175.2001.00448.x.
Campo, C., Segura, J., Fernández, M. L., Guerrero, L., Christiansen, H., & Ruilope, L. M. (2001). A prospective comparison of four antihypertensive agents in daily clinical practice. Journal of clinical hypertension (Greenwich, Conn.), 3(3), 139-44. https://doi.org/10.1111/j.1524-6175.2001.00448.x
Campo, C, et al. "A prospective comparison of four antihypertensive agents in daily clinical practice." Journal of clinical hypertension (Greenwich, Conn.) vol. 3,3 (2001): 139-44. doi: https://doi.org/10.1111/j.1524-6175.2001.00448.x
Campo C, Segura J, Fernández ML, Guerrero L, Christiansen H, Ruilope LM. A prospective comparison of four antihypertensive agents in daily clinical practice. J Clin Hypertens (Greenwich). 2001 May-Jun;3(3):139-44. doi: 10.1111/j.1524-6175.2001.00448.x. PMID: 11430394.
Copy Download .nbib Format: NLM
How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?.

Current hypertension reports

Segura J, Christiansen H, Campo C, Ruilope LM.
PMID: 12948436
Curr Hypertens Rep. 2003 Oct;5(5):426-9. doi: 10.1007/s11906-003-0089-7.

The inhibition of the effects of angiotensin II is necessary to ensure the best degree of renal protection by the simultaneous control of blood pressure (BP) and the achievement of the maximal antiproteinuric capacity. The inhibition can be attained...

Cite
Segura J, Christiansen H, Campo C, et al. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?. Curr Hypertens Rep. 2003;5(5):426-9doi: 10.1007/s11906-003-0089-7.
Segura, J., Christiansen, H., Campo, C., & Ruilope, L. M. (2003). How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?. Current hypertension reports, 5(5), 426-9. https://doi.org/10.1007/s11906-003-0089-7
Segura, Julian, et al. "How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?." Current hypertension reports vol. 5,5 (2003): 426-9. doi: https://doi.org/10.1007/s11906-003-0089-7
Segura J, Christiansen H, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?. Curr Hypertens Rep. 2003 Oct;5(5):426-9. doi: 10.1007/s11906-003-0089-7. PMID: 12948436.
Copy Download .nbib Format: NLM
Disseminated neuroblastomas under 1 year of age: cell biology and prognosis.

Journal of neuro-oncology

Lampert F, Christiansen H, Berner F, Terpe HJ, Berthold F.
PMID: 9049847
J Neurooncol. 1997 Jan;31(1):181-4. doi: 10.1023/a:1005778607661.

Tumor specimens of 203 infants with neuroblastomas of different clinical stages-registered in successive multicenter clinical trials of the German Society of Pediatric Oncology-could be examined for N-myc amplification, chromosome 1-ploidy and-structure, CD44 std. expression (in tumor tissue, and also...

Cite
Lampert F, Christiansen H, Berner F, et al. Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. J Neurooncol. 1997;31(1):181-4doi: 10.1023/a:1005778607661.
Lampert, F., Christiansen, H., Berner, F., Terpe, H. J., & Berthold, F. (1997). Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. Journal of neuro-oncology, 31(1), 181-4. https://doi.org/10.1023/a:1005778607661
Lampert, F, et al. "Disseminated neuroblastomas under 1 year of age: cell biology and prognosis." Journal of neuro-oncology vol. 31,1 (1997): 181-4. doi: https://doi.org/10.1023/a:1005778607661
Lampert F, Christiansen H, Berner F, Terpe HJ, Berthold F. Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. J Neurooncol. 1997 Jan;31(1):181-4. doi: 10.1023/a:1005778607661. PMID: 9049847.
Copy Download .nbib Format: NLM
No association between two polymorphisms of the serotonin transporter gene and combined type attention deficit hyperactivity disorder.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

Xu X, Duman EA, Aysimi E, Anney R, Brookes K, Franke B, Zhou K, Buschgens C, Chen W, Christiansen H, Eisenberg J, Gabriëls I, Manor I, Marco R, Müller UC, Mulligan A, Rommelse N, Thompson M, Uebel H, Banaschewski T, Buitelaar J, Ebstein R, Gill M, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Faraone SV, Asherson P.
PMID: 18452186
Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 05;147(7):1306-9. doi: 10.1002/ajmg.b.30737.

Several independent studies have reported association between serotonin transporter gene (SLC6A4) polymorphisms and attention deficit hyperactivity disorder (ADHD). Five studies found evidence for association between the long-allele of a 44-bp insertion/deletion polymorphism (5-HTTLPR) and ADHD. Another two studies corroborated...

Cite
Xu X, Duman EA, Aysimi E, et al. No association between two polymorphisms of the serotonin transporter gene and combined type attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147(7):1306-9doi: 10.1002/ajmg.b.30737.
Xu, X., Duman, E. A., Aysimi, E., Anney, R., Brookes, K., Franke, B., Zhou, K., Buschgens, C., Chen, W., Christiansen, H., Eisenberg, J., Gabriëls, I., Manor, I., Marco, R., Müller, U. C., Mulligan, A., Rommelse, N., Thompson, M., Uebel, H., Banaschewski, T., Buitelaar, J., Ebstein, R., Gill, M., Miranda, A., Mulas, F., Oades, R. D., Roeyers, H., Rothenberger, A., Sergeant, J., Sonuga-Barke, E., Steinhausen, H. C., Taylor, E., Faraone, S. V., & Asherson, P. (2008). No association between two polymorphisms of the serotonin transporter gene and combined type attention deficit hyperactivity disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 147(7), 1306-9. https://doi.org/10.1002/ajmg.b.30737
Xu, X, et al. "No association between two polymorphisms of the serotonin transporter gene and combined type attention deficit hyperactivity disorder." American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics vol. 147,7 (2008): 1306-9. doi: https://doi.org/10.1002/ajmg.b.30737
Xu X, Duman EA, Aysimi E, Anney R, Brookes K, Franke B, Zhou K, Buschgens C, Chen W, Christiansen H, Eisenberg J, Gabriëls I, Manor I, Marco R, Müller UC, Mulligan A, Rommelse N, Thompson M, Uebel H, Banaschewski T, Buitelaar J, Ebstein R, Gill M, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Faraone SV, Asherson P. No association between two polymorphisms of the serotonin transporter gene and combined type attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 05;147(7):1306-9. doi: 10.1002/ajmg.b.30737. PMID: 18452186.
Copy Download .nbib Format: NLM
Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects.

Psychological medicine

Andreou P, Neale BM, Chen W, Christiansen H, Gabriels I, Heise A, Meidad S, Muller UC, Uebel H, Banaschewski T, Manor I, Oades R, Roeyers H, Rothenberger A, Sham P, Steinhausen HC, Asherson P, Kuntsi J.
PMID: 17537284
Psychol Med. 2007 Dec;37(12):1703-15. doi: 10.1017/S0033291707000815. Epub 2007 May 31.

BACKGROUND: Reaction time (RT) variability is one of the strongest findings to emerge in cognitive-experimental research of attention deficit hyperactivity disorder (ADHD). We set out to confirm the association between ADHD and slow and variable RTs and investigate the...

Cite
Andreou P, Neale BM, Chen W, et al. Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects. Psychol Med. 2007;37(12):1703-15doi: 10.1017/S0033291707000815.
Andreou, P., Neale, B. M., Chen, W., Christiansen, H., Gabriels, I., Heise, A., Meidad, S., Muller, U. C., Uebel, H., Banaschewski, T., Manor, I., Oades, R., Roeyers, H., Rothenberger, A., Sham, P., Steinhausen, H. C., Asherson, P., & Kuntsi, J. (2007). Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects. Psychological medicine, 37(12), 1703-15. https://doi.org/10.1017/S0033291707000815
Andreou, Penny, et al. "Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects." Psychological medicine vol. 37,12 (2007): 1703-15. doi: https://doi.org/10.1017/S0033291707000815
Andreou P, Neale BM, Chen W, Christiansen H, Gabriels I, Heise A, Meidad S, Muller UC, Uebel H, Banaschewski T, Manor I, Oades R, Roeyers H, Rothenberger A, Sham P, Steinhausen HC, Asherson P, Kuntsi J. Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects. Psychol Med. 2007 Dec;37(12):1703-15. doi: 10.1017/S0033291707000815. Epub 2007 May 31. PMID: 17537284; PMCID: PMC3770126.
Copy Download .nbib Format: NLM
Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability.

Cell death and differentiation

Terpe HJ, Christiansen H, Berthold F, Gonzalez M, Altmannsberger M, Schulz A, Lampert F.
PMID: 17180025
Cell Death Differ. 1994;1(2):123-8.

Expression of CD44 was examined by immunohistochemistry in 205 primary neuroblastomas together with histological grading according to the Shimada classification at the time of diagnosis. In addition, Southern blot analysis to determine N-myc gene amplification was carried out in...

Cite
Terpe HJ, Christiansen H, Berthold F, et al. Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Differ. 1994;1(2):123-8
Terpe, H. J., Christiansen, H., Berthold, F., Gonzalez, M., Altmannsberger, M., Schulz, A., & Lampert, F. (1994). Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell death and differentiation, 1(2), 123-8.
Terpe, H J, et al. "Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability." Cell death and differentiation vol. 1,2 (1994): 123-8.
Terpe HJ, Christiansen H, Berthold F, Gonzalez M, Altmannsberger M, Schulz A, Lampert F. Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Differ. 1994;1(2):123-8. PMID: 17180025.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 427 entries